Respiratory syncytial virus infection outbreak among pediatric patients with oncologic diseases and/or BMT

Pediatric Pulmonology

Volumn 45, Issue 3, 2010, Pages 307-311

  Anak, Sema ^a   Atay, Didem ^b   Unuvar, Aysegul ^a   Garipardic, Mesut ^c   Agaoglu, Leyla ^a   Ozturk, Gulyuz ^a   Karakas, Zeynep ^a   Devecioglu, Omer ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b OKMEYDANI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c KSU Medical School   (Turkey)

Author keywords

Oral ribavirin; Pediatric oncology patients; Respiratory syncytial virus

Indexed keywords

IMMUNOGLOBULIN; RIBAVIRIN; VIRUS ANTIGEN;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTIGEN DETECTION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER PATIENT; CHILD; CHILDHOOD CANCER; EPIDEMIC; HODGKIN DISEASE; HOSPITAL PATIENT; HUMAN; IMMUNOFLUORESCENCE TEST; MORBIDITY; MORTALITY; NASOPHARYNGEAL ASPIRATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SYMPTOM; TREATMENT OUTCOME; VIRUS INFECTION;

ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; CHILD, PRESCHOOL; CROSS INFECTION; DISEASE OUTBREAKS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; NEOPLASMS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RIBAVIRIN; TURKEY;

EID: 77449117290     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21184     Document Type: Article

References (23)

1. Ebbert JO, Limper AH. Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome. Respiration. 2005;72:263-269.
2. Raboni SM, Nogueira MB, Tsuchiya LR, Takahashi GA, Pereira LA, Pasquini R, Siqueira MM. Respiratory tract viral infections in bone marrow transplant patients. Transplantation 2003;76:142-146.
3. Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 2000;25:751-755.
4. Abdallah A, Rowland KE, Schepetiuk SK, To LB, Bardy P. An outbreak of respiratory syncytial virus infection in a bone marrow transplant unit: effect on engraftment and outcome of pneumonia without specific antiviral treatment. Bone Marrow Transplant 2003;32:195-203.
5. Sidwell RW. Ribavirin: in vitro antiviral activity. In: Smith RA, Kirkpatrik W, editors. Ribavirin. A broad spectrum anti viral agent. New York: Academic Press; 1980. pp 23-42.
6. Allen LB. Review on in vitro efficacy of ribavirin. In: Smith RA, Kirkpatrick W, editors. Ribavirin. A broad spectrum antiviral agent. New York: Academic Press; 1980. pp. 43-58.
7. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990;12:1139-1146.
8. Sparrelid E, Ljungman P, Ekelof-Andstrom E, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant 1997;19: 905-908.
9. Chakrabarti S, Collingham KE, Holder K, Fegan CD, Osman H, Milligan DW. Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant 2001;28:759-763.
10. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infections in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008;46: 402-412.
11. Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother 1999;43:2451-2456.
12. Schleuning M, Buxbaum-Conradi H, Jaeger G, Kolb HJ. Intravenous ribavirin for eradication of respiratory syncytial virus (RSV) and adenovirus isolates from the respiratory and/or gastrointestinal tract in recipients of allogeneic hematopoietic stem cell transplants. Hematol J 2004;5:135-144.
13. Khushalani NI, Bakri FG,Wentling D, et al. Respiratory syncytial virus infection in the late bone marrow transplant period: report of three cases and review. Bone Marrow Transplant 2001;27:1071-1073.
14. De Vincenzo JP, Hirsch RL, Fuentes RJ, et al. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in paediatric patients undergoing bone marrow transplantation- a compassionate use experience. Bone Marrow Transplant 2000;25:161-165.
15. Anaissie EJ, Mahfouz TH, Aslan T, et al. The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management. Blood 2004;103:1611-1617.
16. Cole PD, Suh JS, Onel K, et al. Benign outcome of RSV infection in children with cancer. Med Pediatr Oncol 2001;37: 24-29.
17. Harrington RD, Hooton TM, Hackman RC, Storch GA, Osborne B, Gleaves CA, Benson A, Meyers JD. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992;165:987-993.
18. Koskenvuo M, Möttönen M, Rahiala J, Saarinen-Pihkala UM, Riikonen P, Waris M, Ziegler T, Uhari M, Salmi TT, Ruuskanen O. Respiratory viral infections in children with leukemia. Pediatr Infect Dis J 2008;27:974-980.
19. Vettenranta K, Ukkonen P, Saarinen UM. RSV infection complicating the therapy of pediatric malignancies: report of six cases. Med Pediatr Oncol 1996;26:261-263.
20. Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial virus infection in children with compromised immune function. N Engl J Med 1986;315:77-81.
21. Sung L, Alonzo TA, Gerbing RB, et al. Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008;51:784-786.
22. Meissner HC, Long SS. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112:1447-1452.
23. Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J 2007;26:1089-1093.